Research ArticleBrief Communication

PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease

Francesco Barbato, Wolfgang P. Fendler, Isabel Rauscher, Ken Herrmann, Axel Wetter, Justin Ferdinandus, Robert Seifert, Michael Nader, Kambiz Rahbar, Boris Hadaschik, Matthias Eiber, Andrei Gafita and Manuel Weber
Journal of Nuclear Medicine December 2021, 62 (12) 1747-1750; DOI: https://doi.org/10.2967/jnumed.121.262120

Article Figures & Data

Figures

  • Figure
  • FIGURE 1.
    FIGURE 1.

    mHSPC disease extent as stratified by CT using CHAARTED criteria and PET using tumor volume and miTNM. Criteria for combined (miTNM and volume) PET volume-of-disease assessment are shown. Dashed line indicates area under curve for approximate 40-cm3 cutoff between PET LVD and PET HVD. Three-year overall survival is given for 40 patients (0 = alive; † = died; all others alive and 3 y after PET not yet reached). diss = disseminated; oligo = oligometastatic; uni = unifocal.

Tables

  • TABLE 1

    mHSPC Disease Extent by CT Versus PSMA PET

    PSMA PET
    CTUnifocalOligometastaticDisseminatedAny M1c
    Unifocal25 (24%)19 (18%)*7 (7%)*2 (2%)*
    Oligometastatic016 (15%)14 (13%)*0
    Disseminated0014 (13%)0
    Any M1c0008 (8%)

    • ↵* PET upstaging in 42 of 105 (40%) patients.

Additional Files

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords